



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/009,854	Felix Kratz	25048-20

INTERNATIONAL APPLICATION NO.

PCT/EP00/05254

I.A. FILING DATE	PRIORITY DATE
06/07/2000	06/10/1999

John B Hardaway III
Nexsen Pruet Jacobs & Pollard
P O Box 10107
Greenville, SC 29603

CONFIRMATION NO. 6344

371 FORMALITIES LETTER



OC000000016658746

Date Mailed: 08/01/2005

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

VONDA M WALLACE

Telephone: (703) 308-9140 EXT 225

PART 2 - OFFICE COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/009,854	PCT/EP00/05254	25048-20

FORM PCT/DO/EO/922 (371 Formalities Notice)



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/009,854	Felix Kratz	25048-20

INTERNATIONAL APPLICATION NO.

PCT/EP00/05254

I.A. FILING DATE	PRIORITY DATE
06/07/2000	06/10/1999

John B Hardaway III
 Nexsen Pruet Jacobs & Pollard
 P O Box 10107
 Greenville, SC 29603

CONFIRMATION NO. 6344

371 WITHDRAWAL NOTICE



OC000000016658718

Date Mailed: 08/01/2005


WITHDRAWAL OF PREVIOUSLY SENT NOTICE

The Acceptance Notice mailed on 06/02/2004 was sent in error and is hereby withdrawn. A corrected Notice is enclosed. The time period for reply runs from the mail date of the enclosed Notice. We apologize for any inconvenience this caused.

VONDA M WALLACE

Telephone: (703) 308-9140 EXT 225

PART 3 - OFFICE COPY



RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 10/009,854

Source: IPWO

Date Processed by STIC: 7/6/04

BEST AVAILABLE COPY

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER

VERSION 4.2 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND

TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS.

<http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm>), EFS Submission

User Manual - ePAVE)

2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 06/05/04):

U.S. Patent and Trademark Office, 220 20th Street S., Customer Window, Mail Stop Sequence, Crystal Plaza Two, Lobby, Room 1B03, Arlington, VA 22202

Revised 05/17/04



IFWO

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/009,854

DATE: 07/06/2004

TIME: 10:15:58

Input Set : A:\K 2892.ST25.txt

Output Set: N:\CRF4\07062004\J009854.raw

BEST AVAILABLE COPY

3 <110> APPLICANT: KTB Tumorforschung
 5 <120> TITLE OF INVENTION: Carrier-drug conjugates
 7 <130> FILE REFERENCE: K 2892
 9 <140> CURRENT APPLICATION NUMBER: US 10/009,854
 C--> 10 <141> CURRENT FILING DATE: 2001-12-11
 12 <150> PRIOR APPLICATION NUMBER: DE 19926475.9
 13 <151> PRIOR FILING DATE: 1999-06-10
 15 <160> NUMBER OF SEQ ID NOS: 9
 17 <170> SOFTWARE: PatentIn version 3.1
 19 <210> SEQ ID NO: 1
 20 <211> LENGTH: 8
 21 <212> TYPE: PRT
 22 <213> ORGANISM: Artificial sequence
 24 <220> FEATURE:
 25 <223> OTHER INFORMATION: Octapeptide which stimulates the cleavage sequence of the
 collage
 26 n chain and is cleaved with particular efficiency by MMP2 and MMP
 27 9.
 29 <400> SEQUENCE: 1
 31 Gly Pro Leu Gly Ile Ala Gly Gln
 32 1 5
 35 <210> SEQ ID NO: 2
 36 <211> LENGTH: 8
 37 <212> TYPE: PRT
 38 <213> ORGANISM: Artificial sequence
 40 <220> FEATURE:
 41 <223> OTHER INFORMATION: Octapeptide which stimulates the cleavage sequence of the
 collage
 42 n chain and is cleaved with particular efficiency by MMP2 and MMP
 43 9.
 45 <400> SEQUENCE: 2
 47 Gly Pro Gln Gly Ile Trp Gly Gln
 48 1 5
 51 <210> SEQ ID NO: 3
 52 <211> LENGTH: 4
 53 <212> TYPE: PRT
 54 <213> ORGANISM: Artificial sequence
 56 <220> FEATURE:
 57 <223> OTHER INFORMATION: Peptide cleaved by cathepsin B
 59 <400> SEQUENCE: 3
 61 Gly Phe Leu Gly
 62 1
 65 <210> SEQ ID NO: 4
 66 <211> LENGTH: 4

Does Not Comply
 Corrected Diskette Needed
 (ps. 3)

67 <212> TYPE: PRT

RAW SEQUENCE LISTING

DATE: 07/06/2004

PATENT APPLICATION: US/10/009,854

TIME: 10:15:58

Input Set : A:\K 2892.ST25.txt

Output Set: N:\CRF4\07062004\J009854.raw

```

68 <213> ORGANISM: Artificial sequence
70 <220> FEATURE:
71 <223> OTHER INFORMATION: Peptide cleaved by cathepsin B
73 <400> SEQUENCE: 4
75 Gly Phe Ala Leu
76 1
79 <210> SEQ ID NO: 5
80 <211> LENGTH: 4
81 <212> TYPE: PRT
82 <213> ORGANISM: Artificial sequence
84 <220> FEATURE:
85 <223> OTHER INFORMATION: Peptide cleaved by cathepsin B
87 <400> SEQUENCE: 5
89 Ala Leu Ala Leu
90 1
93 <210> SEQ ID NO: 6
94 <211> LENGTH: 16
95 <212> TYPE: PRT
96 <213> ORGANISM: Artificial sequence
98 <220> FEATURE:
99 <223> OTHER INFORMATION: Peptide containing two cleavage sites for MMP 2 and MMP9.
101 <400> SEQUENCE: 6
103 Gly Pro Leu Gly Ile Ala Gly Gln Gly Pro Leu Gly Ile Ala Gly Gln
104 1      5      10      15
107 <210> SEQ ID NO: 7
108 <211> LENGTH: 12
109 <212> TYPE: PRT
110 <213> ORGANISM: Artificial sequence
112 <220> FEATURE:
113 <223> OTHER INFORMATION: Peptide containing several cleavage sites for cathepsin B.
115 <400> SEQUENCE: 7
117 Phe Lys Phe Lys Phe Lys Phe Lys Phe Lys Phe Lys
118 1      5      10
121 <210> SEQ ID NO: 8
122 <211> LENGTH: 5
123 <212> TYPE: PRT
124 <213> ORGANISM: Artificial sequence
126 <220> FEATURE:
127 <223> OTHER INFORMATION: Peptide containing several repetitive cleavage sites for
catheps
128      in B.
130 <220> FEATURE:
131 <221> NAME/KEY: MISC_FEATURE
132 <222> LOCATION: (1)..(1)
133 <223> OTHER INFORMATION: X = (Gly)n, n = 2 to 20
136 <400> SEQUENCE: 8
W--> 138 Xaa Phe Lys Phe Lys
139 1      5
142 <210> SEQ ID NO: 9
143 <211> LENGTH: 8

```

Fyi: "N" cannot
define a
range of
nucleotides.

RAW SEQUENCE LISTING

DATE: 07/06/2004

PATENT APPLICATION: US/10/009,854

TIME: 10:15:58

Input Set : A:\K 2892.ST25.txt

Output Set: N:\CRF4\07062004\J009854.raw

144 <212> TYPE: PRT

145 <213> ORGANISM: Artificial sequence

147 <220> FEATURE:

148 <223> OTHER INFORMATION: Octapeptide which is cleaved by MMP9.

150 <400> SEQUENCE: 9

152 Gln Gly Ala Ile Gly Leu Pro Gly

153 1 5

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/10/009,854

DATE: 07/06/2004
TIME: 10:15:59

Input Set : A:\K 2892.ST25.txt
Output Set: N:\CRF4\07062004\J009854.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:8; Xaa Pos. 1 ✓

VERIFICATION SUMMARY

PATENT APPLICATION: US/10/009,854

DATE: 07/06/2004

TIME: 10:15:59

Input Set : A:\K 2892.ST25.txt

Output Set: N:\CRF4\07062004\J009854.raw

L:10 M:271 C: Current Filing Date differs, Replaced Current Filing Date

L:138 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8 after pos.:0